Literature DB >> 8621891

Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts.

J Monteiro1, F Batliwalla, H Ostrer, P K Gregersen.   

Abstract

Long term in vitro culture of clonally expanded CD8+T cells, generally found within the CD57+ or CD28-subset, has generally been unsuccessful, suggesting that these cells may have a limited replicative potential. Telomeric shortening may reflect the action of a "mitotic clock" regulating the number of divisions a cell can undergo. In this study, we have compared the telomeric lengths of CD28-CD8+ and CD28+CD8+ T cells in 10 normal individuals to assess their replicative history. Overall, the telomeric lengths were found to be significantly shorter in the CD28-CD8+ T cell subset compared with the CD28+CD8+ subset. Furthermore, clonally expanded TCRBV11+CD8+ T cells from an individual exhibited telomeric lengths that were 2.9 kb shorter than those found in the polyclonal CD28+CD8+ T cell subset. These findings indicate that clonally expanded CD28-CD8+ T cells have undergone many more rounds of replication than CD28+CD8+ T cells, and consistent with the loss of CD28 expression, they may have reached a state of replicative senescence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621891

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  104 in total

1.  The T cell receptor repertoire of CD8+CD28- T lymphocytes is dominated by expanded clones that persist over time.

Authors:  E N Mugnaini; T Egeland; A Spurkland; J E Brinchmann
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts.

Authors:  T Messele; M Abdulkadir; A L Fontanet; B Petros; D Hamann; M Koot; M T Roos; P T Schellekens; F Miedema; T F Rinke de Wit
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Authors:  G M Gillespie; M R Wills; V Appay; C O'Callaghan; M Murphy; N Smith; P Sissons; S Rowland-Jones; J I Bell; P A Moss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Regulatory functions of CD8+CD28- T cells in an autoimmune disease model.

Authors:  Nader Najafian; Tanuja Chitnis; Alan D Salama; Bing Zhu; Christina Benou; Xueli Yuan; Michael R Clarkson; Mohamed H Sayegh; Samia J Khoury
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 6.  Telomeres and immune competency.

Authors:  Nan-ping Weng
Journal:  Curr Opin Immunol       Date:  2012-05-22       Impact factor: 7.486

Review 7.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

8.  Clonal expansion and TCR-independent differentiation shape the HIV-specific CD8+ effector-memory T-cell repertoire in vivo.

Authors:  Dirk Meyer-Olson; Brenna C Simons; Joseph A Conrad; Rita M Smith; Louise Barnett; Shelly L Lorey; Coley B Duncan; Ramesh Ramalingam; Spyros A Kalams
Journal:  Blood       Date:  2010-04-27       Impact factor: 22.113

9.  Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines.

Authors:  Wai Kan Chiu; Monchou Fann; Nan-ping Weng
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 10.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.